Entelos, Inc. Announces Publication of Its Type 1 Diabetes PhysioLab(R) Platform, a Computer Model to Aid in the Development of Novel Therapeutic Approaches
Published: Jun 02, 2010
FOSTER CITY, Calif.--(BUSINESS WIRE)--Entelos, Inc. has announced a publication in the peer-reviewed journal Clinical and Experimental Immunology describing the Type 1 Diabetes (T1D) PhysioLab® platform, an in silico solution for rapidly streamlining preclinical research through the evaluation of alternative scenarios for therapeutic strategies. Access to a version of the T1D PhysioLab platform is provided by Clinical and Experimental Immunology through supplemental information described in the journal, allowing readers to navigate through the platform to learn about its features and capabilities. To view the abstract, click here.